Wednesday, November 18, 2026 Evidence-led medical research news
The First Cohort
Medical research, with the receipts

Drugs & FDA

93 stories

Drugs & FDA

A Sugar Ring for Niemann-Pick Type C Won FDA Approval After Its Only Randomized Trial Failed

The FDA says 36 children on adrabetadex reached a median survival of 8.5 years, against 4.9 in matched outside controls. Its only randomized trial missed, its price is unannounced, and its label warns of permanent hearing loss.

Drugs & FDA

Inovio's Accelerated-Approval Drug Is Headed for a $460,000 List Price, Matching the Rival the FDA Approved Outright

Inovio expects to list Voceryq at about $115,000 a dose, the same as Precigen's fully approved Papzimeos, then raised about $80.5 million in stock while the trial meant to confirm its benefit still lacks a final protocol.

Drugs & FDA

Bayer's New Stroke Drug Raised Bleeding in the Same 90 Days Its Trial Couldn't Prove a Stroke Benefit

Sunharbo cut ischemic strokes by 2.2 percentage points over a median 567 days. In the first 90 days its stroke benefit missed statistical significance, and the FDA says major bleeding went up.

Drugs & FDA

FDA Fast-Tracks a J&J Head and Neck Cancer Drug on Tumor Shrinkage, and Its Announcement Names No Confirmatory Trial

Tumors shrank in 42 percent of patients in a 102-person trial with no control arm. The FDA says clinical benefit is unconfirmed and confirmatory studies are required, and its announcement does not name one.

Drugs & FDA

Edwards' Case for Earlier Heart Valves Rests on Hospital Stays, Not Survival

Edwards' own trial halved the share of moderate aortic stenosis patients hospitalized for heart failure, but deaths ran 8.4 percent with early TAVR versus 7.3 percent under initial surveillance, and 57.4 percent of that arm got the valve within two years anyway.

Drugs & FDA

Inovio Gets Its First FDA Approval After 7 of 26 Patients Went a Year Without Surgery

In December, the FDA's preliminary view was that Inovio hadn't justified the accelerated pathway. On Friday it granted it, on an uncontrolled trial whose confirmatory study still has no agreed protocol.

Drugs & FDA

Mice Trained to Spot THC Gave the THC Answer for CBN, the Sleep-Gummy Cannabinoid

Mice given CBN twice daily for five days grew tolerant and twitched once a receptor blocker cut it off. A Canopy Growth sleep trial of CBN found about 0.5 fewer awakenings a night and missed its main measure.

Drugs & FDA

Heart Failure Admissions Ran 3.7 Percent Higher for Every Year the West Sold Legal Pot

Fifty million discharge records tie each year of Western dispensary sales to higher heart failure, heart attack and atrial fibrillation admission rates, while the federal rescheduling fight sits frozen before a DEA judge.

Drugs & FDA

The PTSD Magnet Therapy Touting 68 Percent Remission Hasn't Shown Its Placebo Arm

In Wave Neuroscience's earlier sham-controlled trial, veterans on a coil built to deliver no magnetic field improved about two-thirds as much as those on active stimulation. The sham results from the trial behind its FDA clearance still haven't been posted.

Drugs & FDA

Blood Pressure Fell Further on the Switched-Off Ear Clip Than on the Real Device

Daytime systolic pressure fell 5.50 points on a zero-current fake ear clip and 3.15 on the active device. Queen Mary's headline said the stimulation "shows potential."

Drugs & FDA

Six Months Against Twelve: How Essilor's New Myopia Lens Got Called 'Twice as Fast'

Stellest 2.0's six-month numbers sat close to the original lens's one-year result from a separate trial, and a company symposium in London called that twice as fast. The children's lens is on sale abroad and has not been cleared by the FDA.

Drugs & FDA

GSK's Hepatitis B Drug Got a Label That Reaches Patients It Functionally Cured About One Time in 14

Below 1,000 IU/mL of surface antigen, 26 percent of treated patients reached functional cure. Between 1,000 and 3,000, a range the FDA's label also covers, GSK's own counts work out to about 7 percent, for a weekly injection boxed for serious liver reactions and low platelets.

Drugs & FDA

The FDA Fast-Tracked GSK's Rectal Cancer Drug and Left the Trial's Own Scorecard Out of Its Announcement

Independent reviewers found 47 percent of evaluable AZUR-1 patients held a complete response for a year, the trial's registered endpoint. The FDA's announcement quoted friendlier measures instead.

Drugs & FDA

Vaping Beat the Patch in the Strongest Evidence Yet. The WHO Told Governments Not to Allow It.

Eighty randomized trials and nearly 30,000 people put nicotine vapes ahead of patches and gum, with high-certainty evidence. More than half of adults believe vaping is as dangerous as smoking. The agencies that warned them never had the trial data on their side.

Drugs & FDA

Twenty-Six Days After Altria Sued, the FDA Said It May Scrap Its Vape Rulebook

Out of 26.6 million nicotine-product applications since 2020, the FDA authorized 75. Now, with a tobacco giant's lawsuit named in its own notice, the agency says it may replace the whole framework.

Drugs & FDA

The First-Line Glaucoma Drop That Flatters Its Own Pressure Reading

Across 128 eyes followed at one VA clinic, the corneas that thinned most on prostaglandin drops made the pressure gauge read 3.3 mm Hg low, and those eyes lost visual field nearly twice as fast.

Drugs & FDA

The FDA's 'Historic' Growing Heart Valve Has Been Stretched in Two Children

Children who get a new heart valve before age 2 can face up to five open-heart surgeries. Edwards' polymer valve is built to end that, and the trial behind its approval widened it in two of 62 kids.

Drugs & FDA

After 56 Years of 'No Accepted Medical Use,' the FDA Wants Help Testing Ibogaine

Howard Lotsof said one dose ended his heroin withdrawal in 1962. The same alkaloid can stop a heart. The FDA has opened 45 days of comment on how to test it without killing anyone.

Drugs & FDA

A Hundred Thousand Dollars, Two Inches, and a New Calculator for Sorting Short Children

About $100,000 buys a healthy short child two inches of height. A new calculator predicts who responds best, and it joins a field where some of the biggest datasets belong to the companies selling the hormone.

Drugs & FDA

Kennedy's Peptide Plan Reaches the White House, and Wall Street Is Already Counting the Money

Peptides already sell on a Queens bodega shelf, so moving them into licensed pharmacies is progress. Whether it protects anyone depends on one missing rule: test each lot and report every injury.

Drugs & FDA

GenSight's Blindness Gene Therapy Reached the NEJM on the Same Day It Reported €0.7 Million in Cash

Seven of ten patients blinded by retinitis pigmentosa sensed more light through special goggles after one gene injection, in an uncontrolled trial whose sponsor held €0.7 million on September 30 and warned it may not survive the year.

Drugs & FDA

FDA's Anktiva Approval for Papillary-Only Bladder Cancer Cites No Papillary-Only Patients

Seventeen months after refusing even to review ImmunityBio's application, the FDA expanded Anktiva's label by extrapolating from carcinoma in situ, and its announcement never mentioned the 80 papillary-only patients the company had actually studied.

Drugs & FDA

A Heart-Failure Implant Won by 40 Points on a Questionnaire Filled Out by Patients Who Knew Which Arm They Were In

Patients given Berlin Heals' microcurrent implant reported quality-of-life gains eight times the control arm's in an open-label trial. The blood marker and exercise test that could have backed them up showed no significant difference, and the company paid for the study.

Drugs & FDA

Terence Tao Fears a Cancer Cure Nobody Can Explain. The FDA Clears Cancer Drugs That Never Proved They Extend Life.

Terence Tao says he would want a human expert to understand an AI cancer cure before taking it. The oncologist Vinay Prasad says that misses how medicine already works, and the receipts show the cancer drugs worth fearing are the legible ones approved on a shrinking tumor that never proved they help